Dose-dense adjuvant chemotherapy for primary breast cancer.

Breast Cancer Res 2005 10;7(2):64-9. Epub 2005 Feb 10.

Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer. Nevertheless, the prognosis for patients presenting with extensive axillary lymph node involvement remains suboptimal. In an attempt to improve on the efficacy of existing chemotherapy, a phase III intergroup trial led by the Cancer and Leukemia Group B (CALGB 97-41) was designed, which tested a mathematical model of tumor growth based on the Norton-Simon hypothesis. This hypothesis, developed about 3 decades ago, and the kinetic model derived from it, created the basis of the concepts of dose density and sequential therapy, both of which were tested in CALGB 97-41. This large prospective randomized trial demonstrated that shortening the time interval between each chemotherapy cycle while maintaining the same dose size resulted in significant improvements in disease-free and overall survival in patients with node-positive breast carcinoma. This finding is highly relevant and has immediate implications for clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr1007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064124PMC
January 2006
5 Reads

Publication Analysis

Top Keywords

breast cancer
8
calgb 97-41
8
adjuvant chemotherapy
8
group calgb
4
designed tested
4
97-41 designed
4
chemotherapy cycle
4
mathematical model
4
tumor growth
4
time interval
4
interval chemotherapy
4
model tumor
4
leukemia group
4
tested mathematical
4
cancer leukemia
4
phase iii
4
97-41 large
4
chemotherapy phase
4
size improvements
4
existing chemotherapy
4

References

(Supplied by CrossRef)

A Jemal et al.
CA Cancer J Clin 2004

F Levi et al.
Ann Oncol 2004

Early Breast Cancer Trialists' Collaborative Group et al.
Lancet 1998

IC Henderson et al.
J Clin Oncol 2003

EP Mamounas et al.
Proc Am Soc Clin Oncol 2003

JM Nabholtz et al.
Proc Am Soc Clin Oncol 2002

W Hryniuk et al.
J Clin Oncol 1986

HE Skipper et al.
Cancer Treat Rep 1986

B Fisher et al.
J Clin Oncol 1997

B Fisher et al.
J Clin Oncol 1999

S Rodenhuis et al.
N Engl J Med 2003

Similar Publications